Europe Cancer Screening Market

Europe Cancer Screening Market Size (2022 To 2027)

The cancer screening market in Europe is anticipated to rise at a CAGR of 7.29% from 2022 to 2027.

The growing prevalence of cancer across the European region is the primary factor driving the European cancer screening market growth. According to a survey in 2020, nearly 4 million new cancer cases were reported in Europe. European cancer cases are also seen in children between 15-19 years. Genetic disorders, increasing consumption of alcohol, obesity, and having an unhealthy diet are a few reasons for different types of cancers. As a result, the population is seeking cancer screening which helps to prevent any critical situations due to cancer.

In addition, the growing adoption of technological developments to perform cancer screening tests is fuelling European market growth. Manufacturers are focusing on developing screening equipment with advanced technology, such as artificial intelligence, on supporting the demand for screening devices in the European market. They also focus on accurate results, which do not need further tests to confirm cancer in the patient's body. Furthermore, with the increasing number of cancer types among the population, key players are manufacturing different types of equipment used for cancer screening tests. As a result, reputed organization and the local government have increased their investment in developing devices that promote market growth.

Furthermore, the growing awareness regarding early disease diagnosis promotes the European cancer screening market. Due to the COVID-19 pandemic, people are becoming more concerned about their health and prefer regular health check-ups to avoid health risks, which is expected to boost the usage of cancer screening tests. The governments of European countries have been conducting several awareness programs to spread awareness regarding the availability of screening tests in hospitals and provide favorable reimbursement policies for screening tests.

However, the growing usage of refurbished medical devices to conduct cancer screening tests may result in errors or incorrect reports, which may severely impact the patients. Such factors are hampering the growth of the European cancer screening market. Furthermore, the unavailability of screening programs in some of the underdeveloped areas of Europe and the poor awareness levels regarding various screening tests further hinder the European market growth.

This research report on the Europe cancer screening market has been segmented and sub-segmented into the following categories.

By Cancer:

• Lung Cancer
• Blood Cancer
• Bone Cancer
• Gall Bladder Cancer
• Testicular Cancer
• Thyroid Cancer
• Breast Cancer
• Others

By Technique:

• Imaging Techniques
  • CT Scan
  • MRI
  • Others
• Endoscopy
  • Colonoscopy
  • Sigmoidoscopy
  • Others
• Biopsy and Cytology Tests
  • Needle Biopsy
  • CT-Guided Biopsy
  • Others
• Genomic and Molecular tests
  • Next Generation Sequencing (NGS)
  • RT- PCR
  • Others

By Stage:

• TNM Stages
• Stages 0, 1, 2, 3, 4
• Prognostic Factors
• Others

By Gender:

• Men 
• Women

By Country:

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

The European region accounted for a promising global market share in 2021. During the forecast period, the European cancer screening market is anticipated to showcase a healthy CAGR owing to the growing healthcare expenditure by the people and an increase in cancer screening centers. EU Cancer Screening Scheme has been introduced to reduce cancer cases in this region. The scheme implements a new way to support member states by increasing cancer screening uptake. The European Commission has also expanded screening programs for tumors.

Germany had the most significant share of the European market in 2021. German government conducted several programs for different types of cancer, such as bowel, breast, lung, and others. These programs help to provide a clear view of the benefits of having a screening test for a quality life. They also provide video-based information about all types of screening procedures. For example, in Germany, the government has conducted mammography screening programs for women 50-60 years of age to reduce breast cancer cases.

The UK is anticipated to showcase a healthy CAGR during the forecast period. Cancer screening programs are also being conducted in the United Kingdom, which helps diagnose cancer early before observing any symptoms in the body and helps provide successful treatment to increase the patient’s life span. According to a recent survey in the United Kingdom, nearly 1 in 8 women are diagnosed with breast cancer in their lifetime. As a result, early detection helps in a good chance of recovery.

KEY MARKET PLAYERS:

DiaSorin S.p.A., Epigenomics AG, Techlab, Inc., Positive Biosciences Limited, MedGenome Labs Ltd, 20/20 GeneSystems, AB SCIEX, Abbott Laboratories, Abcodia Ltd., and Abingdon Health Ltd are some of the notable players in the European cancer screening market.